Steroid refractory severe ulcerative colitis after kidney transplantation successfully treated with infliximab

Clin J Gastroenterol. 2023 Dec;16(6):848-853. doi: 10.1007/s12328-023-01857-z. Epub 2023 Sep 16.

Abstract

A 54-year-old man underwent kidney transplantation at the age of 50 for end-stage renal failure owing to diabetic nephropathy. The patient was subsequently treated with three immunosuppressive drugs (tacrolimus, mycophenolate mofetil, and methylprednisolone) to prevent organ rejection, and no renal failure was noted. He visited our department with bloody stools and diarrhea, and a colonoscopy revealed mucosal edema and redness of the entire colon. After excluding infection and drug-induced enteritis based on the endoscopic and pathological findings, he was diagnosed with ulcerative colitis (UC). He was admitted and received a high dose of steroids, but did not demonstrate improvement. We initiated infliximab (IFX), and his symptoms improved within 3 days. After the second IFX treatment, the patient achieved clinical remission and was discharged. After the third IFX dose, the biomarker level became normal, and a colonoscopy after the fourth IFX dose revealed that all ulcers had become scarred and achieved endoscopic remission. The patient continued all medications to prevent organ rejection after the onset of UC and had no graft dysfunction or infection for 1 year.

Keywords: De novo IBD; Infliximab; Kidney transplantation; Steroid refractory; Ulcerative colitis.

Publication types

  • Case Reports

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / pathology
  • Colitis, Ulcerative* / surgery
  • Colonoscopy
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Steroids / therapeutic use
  • Treatment Outcome
  • Ulcer

Substances

  • Infliximab
  • Steroids
  • Gastrointestinal Agents